Tirzepatide is a once-weekly, subcutaneous injectable medication that acts as a dual agonist for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is FDA-approved under the brand name Mounjaro for type 2 diabetes and Zepbound for chronic weight management. By mimicking these gut hormones, it improves glycemic control, increases satiety, and significantly reduces body weight.
Tirzepatide is a once-weekly, subcutaneous injectable medication that acts as a dual agonist for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is FDA-approved under the brand name Mounjaro for type 2 diabetes and Zepbound for chronic weight management. By mimicking these gut hormones, it improves glycemic control, increases satiety, and significantly reduces body weight.